SCHEMBL30765701

SCHEMBL30765701

C[C@@H](Nc1cnc(-c2ccccc2F)n(CC(=O)OC(C)(C)C)c1=O)c1ccc2c(c1)oc1ccccc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
HPGD P15428 1/20 0.35
KDM4E B2RXH2 2/20 0.35
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
ALOX15 P16050 1/20 0.34
ELANE P08246 3/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
JAK3 P52333 1/20 0.34
GAA P10253 2/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558470 0.89 LMNA (0.37) ALDH1A1HPGDKDM4ELMNATP53
SCHEMBL30765981 0.89 LMNA (0.37) ALDH1A1HPGDKDM4ELMNATP53
SCHEMBL30765722 0.88 ELANE (0.35) ALDH1A1HPGDKDM4ELMNAELANE
SCHEMBL30765879 0.87 GAA (0.41) ALDH1A1HPGDLMNATP53ALOX15
SCHEMBL30765975 0.87 ALDH1A1 (0.35) ALDH1A1HPGDKDM4ELMNAELANE
SCHEMBL31558585 0.87 ALDH1A1 (0.35) ALDH1A1HPGDKDM4ELMNAELANE
SCHEMBL30765563 0.85 PDE2A (0.40) ALDH1A1KDM4EELANE
SCHEMBL30765944 0.84 ALDH1A1 (0.37) ALDH1A1HPGDKDM4ELMNATP53
SCHEMBL30765991 0.84 ELANE (0.42) ALDH1A1KDM4ELMNAELANEJAK2
SCHEMBL30766151 0.84 ELANE (0.37) ALDH1A1HPGDLMNATP53ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed